摘要
目的探讨奥沙利铂联合卡培他滨对老年胃癌根治术后患者的T淋巴细胞免疫状况及肿瘤因子的影响。方法选取120例老年胃癌患者,随机分为观察组和对照组各60例。对照组采用氟尿嘧啶,亚叶酸钙联合奥沙利铂治疗,观察住采用奥沙利铂联合卡培他滨治疗。治疗4周后,比较2组患者治疗前后T淋巴细胞的免疫状况以及肿瘤因子含量的变化,比较2组患者治疗后无进展生存期、化疗周期、1年生存率以及治疗期间不良事件的发生情况。结果治疗后,观察组患者不良事件的发生率为18.33%,显著低于对照组的30.00%(P<0.05);观察组患者CD3+、CD8+和CD4+的含量均显著高于对照组,癌胚抗原(CEA)、CA242和CA199的含量均显著低于对照组(P<0.05);观察组患者的化疗周期、1年生存率和无进展生存期均显著优于对照组(P<0.05)。结论老年胃癌患者根治术后采用奥沙利铂联合卡培他滨进行治疗,能够有效降低对患者正常组织的影响,改善患者的免疫功能,降低不良事件的发生。
Objective To explore the effect of oxaliplatin combined with capecitabine on T lymphocyte immune status and tumor factors in elderly patients with radical gastrectomy for gastric cancer. Methods Totally 120 elderly patients with gastric cancer were selected and randomly divided into observation group and control group,60 cases in each group. The control group was treated with fluorouracil,leucovorin and oxaliplatin,while observation group was treated with oxaliplatin combined with capecitabine. After 4 weeks of treatment,the immune status of T lymphocytes and the changes of the content of tumor factors were compared between the two groups before and after treatment,the progression free survival period,chemotherapy cycle,1-year survival rate and the occurrence rate of adverse events during the treatment were compared between the two groups. Results The incidence rate of adverse events was 18. 33% in the observation group,which was significantly lower than 30% in the control group（ P〈0. 05）. Thecontents of CD3^＋,CD8^＋and CD4^＋in the observation group were significantly higher than those in the control group,and the contents of CEA,CA 242 and CA 199 were significantly lower than those in the control group（ P〈0. 05）. The chemotherapy cycle,the 1-year survival rate and progression free survival time of the observation group were significantly better than those of the control group（ P〈0. 05）. Conclusion Oxaliplatin combined with capecitabine can effectively reduce the side effect on the normal tissue,improve the immune function and reduce the occurrence rate of adverse events in the elderly patients with gastric cancer.
作者
冯勇军
陈东祥
罗飞
向进见
胡小苗
肖宝来
李明忠
FENG Yongjun;CHEN Dongxiang;LUO Fei;XIANG Jinjian;HU Xiaomiao;XIAO Baolai;LI Mingzhong(Department of Oncologic Surgeu,Tumor Hospital of Jingzhou First People＇s Hospital,Jingzhou,Hubei,434000;Department of Gastrointestinal Surgery,Jingzhou First People＇s Hospital,Jingzhou,Hubei,434000)
出处
《实用临床医药杂志》
CAS
2018年第13期56-59,共4页
Journal of Clinical Medicine in Practice
